YUNNAN BAIYAO(SZ:000538)2025-04-11 09:24Group 1: Marketing and Sales Performance - The pharmaceutical marketing network covers all provinces, districts, counties, and townships in China, with a focus on 5,000 leading chain stores and over 400,000 retail outlets, achieving high coverage and market control, especially in East China, Hunan, Hubei, and Yunnan [2] - In 2024, Yunnan Baiyao toothpaste maintained the top market share in the domestic all-channel market [3] - During major sales events like "618" and "Double Eleven," Yunnan Baiyao's oral health brand ranked first in online oral care [4] Group 2: Product Development and Innovation - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with promising stability and safety results reported in November [5] - The company’s subsidiary, Yunke Medical, received approval for clinical trials of INR102, a new radioactive treatment for metastatic castration-resistant prostate cancer [5] Group 3: Dividend Distribution - The company plans to distribute a cash dividend of 11.85 CNY per 10 shares based on a total share capital of 1,784,262,603 shares, with a total cash dividend amounting to 4,278,661,722.00 CNY, accounting for 90.09% of the net profit attributable to shareholders in 2024 [7]